Loading... Please wait...
Global Market Research Information Network
Connecting to intelligent information in the electronic age.
Market Research Categories
- Advanced Materials
- Advanced Technologies
- Aerospace Industry
- Automotive
- Banking and Finance
- Biotechnology
- Business and Consumer Appliances
- Chemicals and Minerals
- Communications Technology
- Electronics and Semiconductors
- Energy
- Industrial Supplies and Accessories
- Information Technology
- Leisure and Entertainment
- Machinery
- Medical Equipment and Supplies
- Merchandising
- Metals and Metal Products
- Nanotechnology
- Security
- Transportation Industry
- Asia Market
- European Market
- Other Research
- Upcoming Reports
New Publications
-
CBRN Defence Market Report USD $2,502.00 -
Commercial Roofing Materials: The North American Market USD $4,850.00
-
The Global Market for Nanoclays and Nanofillers USD $5,000.00
-
The Global Market for Nanotechnology in Textiles USD $1,160.00
-
- Home
- Medical Equipment and Supplies
- Pharmaceuticals
- Antivirals - Global Strategic Business Report
Summary
This report analyzes the worldwide markets for Antivirals in US$ Million. The major product segments analyzed are HIV Antivirals (Reverse Transcriptase Inhibitors (RTIs) (Nucleotide Reverse Transcriptase Inhibitors (NRTIs), and Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)), and Protease Inhibitors (PIs), Hepatitis B & C Antivirals (Hepatitis C Antivirals, and Hepatitis B Antivirals), Herpes Simplex Virus (HSV) Antivirals, Influenza Antivirals, Respiratory Syncytial Virus (RSV) Antivirals, and Human Papilloma Virus (HPV) Antivirals. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual forecasts are provided for the period of 2000 through 2010. The report profiles 139 companies including many key and niche players worldwide such as Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc., Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Schering-Plough Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
ANTIVIRALS MCP-1761
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions and Scope of Study I-3
HIV Antivirals I-3
NRTIs I-4
NNRTIs I-4
Protease Inhibitor (PI) I-4
Other HIV Antivirals I-4
Hepatitis B & C Antivirals I-4
Hepatitis B Antivirals I-5
Hepatitis C Antivirals I-5
Herpes Simplex Virus (HSV) Antivirals I-5
Influenza Antivirals I-5
Respiratory Syncytial Virus (RSV) Antivirals I-6
Human Papilloma Virus (HPV) Antivirals I-6
Other Antivirals I-6
II. EXECUTIVE SUMMARY
1. Market Overview II-1
Viruses, a Difficult - to - Treat Class of Parasites II-1
United States - The Largest Market for Antivirals Globally II-1
Five Major Antivirals Dominate the Overall Antivirals Arena II-2
Table 1: Worldwide Infectious Disease Drugs Market by Class:
2005 Percentage Share Breakdown by Type for Antivirals,
Quinolones, Macrolides, Penicillins, Cephalosporins,
Antifungals, Tetracyclines, Erythromycins and Other
Therapies in US$ million (includes corresponding
Graph/Chart) II-2
Anti-HIV Drugs - The Largest Antivirals Category Worldwide II-2
US - Largest Region, and Japan - Fastest Growing Region for
HIV Antivirals II-3
Table 2: World HIV Antivirals Market by Geographic Region -
US, Japan, Europe and Rest of World (excluding Japan) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 & 2010 (includes corresponding
Graph/Chart) II-3
Table 3: World HIV Antivirals Market by Geographic Region -
Percentage Share Breakdown for US, Japan, Europe, and Rest of
World (excluding Japan) for the Year 2006 (includes
corresponding Graph/Chart) II-3
Leading Players and Drugs II-4
Top 10 HIV Antiviral Drug Candidates by Global Sales II-4
New Drugs in Pipeline to Boost up the HIV Antivirals Sales II-4
Hepatitis Antivirals - A Significant Market II-4
US Dominates the Hepatitis B & C Antivirals Market II-5
Table 4: World Hepatitis B & C Antivirals Market by
Geographic Region - US, Japan, Europe and Rest of World
(excluding Japan) with Annual Sales Figures in US$ Million
for Years 2006 & 2010 (includes corresponding Graph/Chart) II-5
Hepatitis C Antivirals - The Fastest Growing Antivirals
Segment II-5
U S Dominates the Hepatitis C Antivirals Market II-6
Table 5: World Hepatitis C Antivirals Market by Geographic
Region - US, Japan, Europe and Rest of World (excluding
Japan) with Annual Sales Figures in US$ Million for Years
2006 & 2010 (includes corresponding Graph/Chart) II-6
The US Dominates the Hepatitis B Antivirals Market II-6
Table 6: World Hepatitis B Antivirals Market by Geographic
Region - US, Japan, Europe and Rest of World (excluding
Japan) with Annual Sales Figures in US$ Million for Years
2006 & 2010 (includes corresponding Graph/Chart) II-7
Growing Patient Population to Drive up Hepatitis B Drugs Market II-7
Influenza Anti-Virals II-7
Rising Threat of Avian Flu to Drive up the Market for
Antivirals II-7
Herpes and Respiratory Antivirals II-8
HSV/VZV Drugs Dominate the Herpes and Respiratory Antivirals
Market II-8
Launch of New Drugs to Drive up the Market for Respiratory
Antivirals II-8
2. Competitive Landscape II-9
Players Active in the HIV Antivirals Market II-10
Table 7: Leading Drug Brands for HIV Infection in the World:
2005 Sales (in $ million) for Combivir, Kaletra, Viread,
Reyataz, Sustiva, Trizivir, Epivir, and Epzicom/ Kivexa
(includes corresponding Graph/Chart) II-10
Major HIV Antivirals Brands Available in the Market II-10
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Brands - II-10
Epivir (Lamivudine) II-10
Retrovir (Zidovudine) II-10
Combivir (Epivir+Retrovir) II-11
Videx (Didanosine) II-11
Zerit (Stavudine) II-11
Hivid (Zalcitabine) II-11
Protease Inhibitors (PIs) - II-11
Norvir (Ritonavir) II-11
Kaletra (Lopinavir+Ritonavir) II-11
Agenerase (Amprenavir) II-11
(VX-175) Fosamprenavir II-12
VX-385 II-12
Fusion Inhibitors - II-12
Fuzeon (Enfuvirtide) II-12
Players Active in the Hepatitis B Virus (HBV) Drugs Market II-12
Hepsera Leads the Oral Hepatitis B Antivirals Market II-12
Table 8: Leading Drug Brands for Oral Hepatitis B Antivirals:
2006 Percentage Share Breakdown for Hepsera, Epivir HBV and
Baraclude (includes corresponding Graph/Chart) II-12
Table 9: Leading Antivirals Brands for Hepatitis B Infection
in the World: 2005 Sales (in $million) for *Engerix-B,
Havrix, and Twinrix; **Infanrix and Pediarix, and Epivir
(includes corresponding Graph/Chart) II-13
Players in the Hepatitis C Virus (HCV) Drugs Market II-13
Table 10: Leading Drug Brands for Oral Hepatitis B Antivirals
in the World: 2005 Sales (in $million) for Pegasys and
PEG-Intron II-13
Table 11: Leading Players in the Pegylated Interferons
Market in the World: 2006 Percentage Share Breakdown by
Player for Hoffmann-La Roche, Schering-Plough and Others
(includes corresponding Graph/Chart) II-14
Table 12: Leading Therapies for Hepatitis C Infection in the
World: 2006, 2010E and 2015E Percentage Share Breakdown for
Ribavirin, Interferons, Protease Inhibitors, and Nucleoside
Analogs (includes corresponding Graph/Chart) II-14
Players in the Herpes and Respiratory Antiviral Market II-15
Table 13: Leading Brands of the Respiratory Antivirals Market
in the World: 2005 Sales (in $million) for Tamiflu; Synagis;
Infanrix and Pediarix (includes corresponding Graph/Chart) II-15
Players in the Herpes Simplex Virus (HSV) Therapies Market II-15
Table 14: Leading Drug Brands for Oral Herpes Antivirals in
the World: 2004 Sales (in $million) for Valtrex and Zovirax II-16
Major HSV Infection Drugs Available II-16
Zovirax (Aciclovir) II-16
Famvir (Famciclovir) II-16
Foscavir (Foscarnet) II-16
Valtrex (Valaciclovir) II-16
Vectavir/Denavir (Penciclovir) II-17
Abreva (Docosanol) II-17
Players in the Influenza Market II-17
Major Influenza Drugs Available II-17
Symmetrel (Amantadine) II-17
Flumadine (Rimantadine) II-17
Tamiflu (Oseltamivir) II-17
Relenza (Zanamivir) II-18
Players in the Antivirals (Non-HIV) Market II-18
Table 15: Global Leading Players in the Antivirals (Non-HIV)
Market: 2005 Percentage Share Breakdown for GlaxoSmithKline
(GSK), Novartis, Roche, Schering-Plough and Others (includes
corresponding Graph/Chart) II-18
Players Active in the Antiviral Vaccines Market II-18
Table 16: Leading Antiviral Vaccines Sales (in US$ million)
in US/Europe in 2003 (includes corresponding Graph/Chart) II-19
Table 17: Leading Players in the US & **5EU Vaccines Markets:
2005 Percentage Share Breakdown by Player for
GlaxoSmithKline (GSK), Sanofi-Aventis, Merck, *Novartis
(Chiron) and Others (includes corresponding Graph/Chart) II-19
Product Pipeline Development of Hepatitis C Drugs as of 2006 II-20
3. Market Trends & Issues II-21
Increased Investment in R&D to Fuel Growth II-21
Preventative Antivirals Gains Significance II-21
New Drug Types Fuels Up the HIV Drugs Sector II-21
Development of Direct Targeted Antiviral Therapies II-22
Advent of Novel Anti-Viral Peptides II-22
siRNA Shows Potential to Function as Antiviral Agent II-23
Reduction of HIV/AIDS Therapy Costs Boost Market Growth II-23
Combination Drug Therapy Gains Popularity in the Anti-HIV
Drugs Market II-23
Empowering Women to Fight Against Spread of HIV Infection II-23
Prices to Go Up for Novel Antivirals II-24
Competition Scales up for Nucleoside/Nucleotide Analogs Class
of Hepatitis Antivirals II-24
Emergence of Oligonucleotide (ODN) Agents in HIV Drugs Market II-24
PMBs to Invade the Antivirals Market II-24
Acute Shortage Witnessed for the Influenza Vaccine for the
2004-05 Season II-24
New Therapies for Treatment Naïve Hepatitis Patients II-25
Adult and Travel Vaccines to Drive Up the Market for
Antiviral Vaccines II-25
Researches to Develop Antivirals for Other Miscellaneous
Viral Diseases on Full Swing II-25
Growth to Slow Down Considerably for Herpes Antiviral Market II-25
STDs, a Major Concern the World Over II-25
Microbiocides, a New Way to Fight STD and HIV Infections II-26
Spread of HIV Infection Poses a Global Health Risk II-26
4. An Overview of Major Viral Epidemics & Pandemics in the World II-28
HIV/AIDS Pandemics II-28
HIV/AIDS Cases for 2005 in the World II-28
Highlights of AIDS Epidemic II-28
Table 18: Global HIV/AIDS Statistics in 2005 (in Million)
(includes corresponding Graph/Chart) II-29
Table 19: Regional Statistics for HIV/AIDS Cases in 2005 (in
Million) (includes corresponding Graph/Chart) II-30
Table 20: Deaths Due to AIDS Worldwide: Breakdown by Region-
2004 (in Million) (includes corresponding Graph/Chart) II-30
Table 21: HIV/AIDS Cases in Adults and Children Worldwide:
Breakdown by Region-End 2004 II-31
Table 22: Countries With the Highest Number of People Living
with HIV: 2003 (includes corresponding Graph/Chart) II-31
Various Organizations Actively Supports HIV/AIDS Awareness
and Preventive Measures Programs II-32
Table 23: Regional Distribution of Requirement of Funding for
Prevention of AIDS: Percentage Share Breakdown for Africa,
East Asia-Pacific, South & South East Asia, Eastern Europe,
Latin America & Caribbean Region, and North Africa & Middle
East in 2006 (includes corresponding Graph/Chart) II-32
Table 24: Regional Distribution of Requirement of Funding for
Treatment and Care of AIDS: Percentage Share Breakdown for
Africa, Latin America & Caribbean Region, East Asia-Pacific,
Eastern Europe, South & South East Asia, and North Africa &
Middle East in 2006 (includes corresponding Graph/Chart) II-32
Hepatitis B Virus (HBV) Infection Epidemic II-32
Hepatitis C Virus (HCV) Infection Epidemic II-33
Table 25: Diagnosis of Hepatitis C Infection in the World:
2005 Percentage Share Breakdown by Transmission Category for
Injecting Drug Use (IDU), Sexual Contact, Contaminated Blood
Transfusion and Others (includes corresponding Graph/Chart) II-33
Influenza - Major Outbreaks II-34
5. Anti-Virals : Product Overview II-35
What are Viruses? II-35
RNA & DNA Viruses II-35
Emergence of Antivirals II-35
Functions of Antivirals II-36
Design Strategies for Antivirals Drugs II-36
Vaccines, the Antivirals for Initial Stage of Viral Infection II-36
Antivirals for Other Stages of Viral Life Cycle II-36
Entry Blockers II-36
Viral Component Replication Blockers II-37
Viral Component Assimilation Blockers II-37
Antisense Molecules II-37
Synthetic Ribozymes II-37
Protease Inhibitors II-38
Blockers for Release of Completed Viruses from the Host Cell II-38
Other Types of Antivirals II-38
Interferons II-38
Synthetic Monoclonal Antibodies II-38
Factors Governing Developments in Antiviral Technology II-38
6. Major Viral Infections and Treatment Worldwide II-39
Human Immunodeficiency Virus (HIV) II-39
Transmission of HIV Infection II-39
Infection Process - Targets for HIV Therapy II-40
Symptoms of the Infection II-40
Most Vulnerable Demographics for HIV Infection II-41
Preventive Methods for Controlling HIV Infection II-42
Methods for the Measurement of Viral Load in Patients II-42
Methods for Determining Drug Resistance in HIV Positive
Patients II-42
Major HIV/AIDS Testing Methods Available II-43
Diagnostic Tests II-43
I. Antibody Tests II-43
A. HIV-1 Screening Tests II-43
a. Enzyme-linked Immunosorbent Assays/ Enzyme
Immunoassays (ELISA/EIA) II-43
b. Home AccessHIV-1 test system/Dried Blood Spot II-44
c. Rapid Tests... II-44
B. HIV-1 Antibody Confirmatory Tests II-44
a. The Western Blot Test II-44
b. Indirect Immunofluorescent Antibody Assay (IFA) II-44
c. Line Immunoassay II-45
d. Radioimmunoprecipitation Assay (RIPA) II-45
C. HIV-2 Diagnostic Tests and HIV Group "O II-45
Major Trends in the HIV/AIDS Testing Market II-45
Rapid Testing- Displays High Potential II-45
FDA Approved Rapid HIV Tests in US II-46
Molecular Diagnostics Register Strong Growth in Blood
Screening Markets II-46
Ultra-Rapid HIV-screening tests- A Strong Fight against
HIV-Epidemic II-46
Emergency Room Testing to Help HIV Diagnosis II-46
Treatments Available for HIV/AIDS Infections II-46
Major HIV/AIDS Drug Categories Available II-47
NRTIs II-47
NNRTIs II-47
GW695634 II-47
Protease Inhibitor (PI) II-48
(VX-175) Fosamprenavir II-48
VX-385 II-48
Integrase Inhibitors (IIs) II-48
S-1360 II-48
Entry Blockers II-48
Fusion Inhibitors II-49
Fuzeon (Enfuvirtide) II-49
Antiviral siRNAs II-49
New Products in Pipeline II-49
HIV Vaccines II-49
Hepatitis Infection II-50
Acute Hepatitis Infection II-50
Chronic Hepatitis Infection II-50
Treatment Regimens for Hepatitis Infection II-50
Interferons II-50
Standard Interferons II-51
Pegylated Interferons II-51
Pegasys II-51
N & PEG-Intron Redipen II-51
Pegasys Pack II-51
N & Pegatron II-51
Ribavirin II-51
Types of Hepatitis Infection based on Strains II-52
Hepatitis A Virus (HAV) Infection II-52
Hipatitis B Virus II-52
Hepatitis B Virus (HBV) Infection II-52
Treatments Available for Chronic HBV Infection II-52
Vaccines Dominates the Category II-52
Antiviral Drugs Available II-53
Hepatitis C Virus (HCV) Infection II-53
Treatments Available for Chronic Hepatitis C Infection II-53
Products in Pipeline II-54
Some Alternative Treatments II-54
Hepatitis D Virus (HDV) Infection II-54
Hepatitis E Virus (HEV) Infection II-55
Herpes Simplex Virus (HSV) Infection II-55
HSV-1 Infection II-55
HSV-2 Infection II-56
Neonatal Herpes Simplex Infection II-56
Treatments Available for HSV Infection II-56
Table Containing Major HSV Drugs along with their Patent
Expiry Dates II-56
HSV Antivirals Available in the Market II-57
Treatments for Opthalmic Viral Infections II-57
Cytovene (Ganciclovir) II-57
Vistide (Cidofovir) II-57
Foscavir (Foscarnet) II-57
Vaccines Against HSV Infection II-58
Respiratory Viruses Infections II-58
Influenza Virus II-58
Influenza A Virus II-59
Avian Flu II-59
Influenza - Brief History II-59
Transmission of Influenza Infection II-59
Treatments for Respiratory Viruses II-59
Influenza Vaccines II-60
Respiratory Syncytial Virus (RSV) Infection II-60
Other Respiratory Viruses II-61
Treatments for RSV and other Respiratory Viral Infections II-61
Human Papilloma Virus (HPV) II-61
Treatments Available for HPV Infection II-61
Other Types of Viral Diseases II-62
Treatment Options Available for Other Types of Viral Diseases II-62
Overview of Antiviral Vaccines II-62
7. International Organizations Supporting Preventative and
Treatment Programs for Viral Infections II-64
UNHCR II-64
UNICEF II-64
WFP II-64
UNDP II-64
UNPF II-65
UNODC II-65
ILO II-65
UNESCO II-65
WHO II-65
World Bank II-66
National AIDS Trust II-66
8. Product Developments and Launches II-67
Bristol-Myers Unveils Baraclude in India II-67
Chinese and US Researchers Together Develop Purified
Antiviral Compounds II-67
Celldex to Develop a Fusion Protein CDX 2401 II-67
PDSC Launches a Germicidal Disinfectant, Medic Kleen II-67
REPLICor to Develop Antiviral Drugs II-67
Valeant Pharmaceuticals to Develop Viramidine(R) II-68
Biota Discovers a New Group of Antiviral Drugs against RSV II-68
Serum Launches Q-Vac, a Combination Vaccine II-68
Chongqing Jiachen to Produce Hepatitis B Vaccine II-68
IIL Decides to Roll Out Five Vaccines in Indian Market II-68
Shanta Biotechnics to Foray into US Markets with AlphaFeto
and Shanvac B II-69
GSK Launches Hepsera for Chronic Hepatitis B II-69
Viral Therapeutics Takes Over Development Rights to
Recombinant Human Protein II-69
Biota Inc Introduces New AZT Nucleotide Mimic Drug for HIV/AIDS II-69
SciGen Ltd Introduces Sci-B-Vac Vaccine for Hepatitis B in
Hong Kong II-69
Aurobindo Pharma Ltd Launches Indivex and Stavex Anti-HIV Drugs II-70
Trimeris and Roche Collaboratively Develops Two Fusion
Inhibitors II-70
9. Recent Industry Activity II-71
Adventrx Takes Over SD Pharmaceuticals II-71
Nutra Pharma to Acquire ReceptoPharm II-71
Dynavax Acquires German Rhein Biotech II-71
Barrier Acquires Rights to Market Denavir from Norvartis II-71
Chimerix Acquires Leroy Townsend Library of Lead Drug Candidates II-71
Sareum Collaborates with Idenix to Develop Antivirals II-72
CSIRO Collaborates with Bath University to Create an Oral
Antiviral Agent II-72
GlaxoSmithKline and Shionogi to Co-Develop HIV Drugs II-72
Inovio Biomedical Corporation Enters into an Agreement with
Tripep AB II-72
Roche Partners with Trimeris to Develop HIV Fusion Inhibitor
Drugs II-73
Pfizer and Monogram Execute a Non-Exclusive Collaboration II-73
Novartis Enters into an Agreement with Human Genome Sciences II-73
Medivir Inks Licensing Deal with Tibotec for HBV and HIV Drugs II-73
Boehringer to Enhance its Canadian Antiviral Research Center II-74
GSK Receives Pediatric Extension of Hevrix Vaccine in the US II-74
GSK Completes Phase II Clinical Trial on Promacta II-74
Schering-Plough Undertakes Clinical Trials on Some Hepatitis
Products II-74
Gilead Sciences and Merck Conducts Clinical Trials (Phase I /
II) on HIV Integrase Inhibitor II-74
Vertex to Start Phase IIb Trials for VX-950 II-74
Schering-Plough Starts Phase II Trials for SCH 503034 II-75
Panacos Pharmaceuticals Initiates Phase 2b Studies on Bevirimat II-75
Immune Response Corporation Initiates IR103 Phase II Trial II-75
Health Enhancement Products Inc to Conduct ProAlgaZyme
Clinical Trial II-75
Novartis Secures FDA Approval for Famvir II-75
Novelos Therapeutics, Inc Gains FDA Acceptance of INDA for
NOV-205 II-76
Gilead Sciences and Bristol-Myers-Squibb Obtains FDA License
for Atripla II-76
Tibotec Obtains FDA Approval for Darunavir II-76
Amazon Receives Consent for Phase I/II Trials for AMZ0026 II-76
MedImmune Applies for Supplemental License for CAIV-T II-77
FermaVir Pharmaceuticals Obtains FDA Approval for Further
Studies on Antiviral Drug Candidate II-77
Abbott Obtains FDA Assent for ABBOTT PRISM and PRISM Blood
Screening II-77
Abbott Receives Authorization from European Commission to
Market Kaletra II-77
Schering-Plough Receives Marketing Approval for PEG-INTRON
and REBETOL Drugs II-77
Idenix and Novartis Submit Drug Application to European
Regulators for Telbivudine II-78
Merck Obtains FDA Approval for Marketing GARDASIL Vaccine II-78
Merck's GARDASIL Vaccine Gets CHMP's Positive Opinion II-78
Boehringer Ingelheim Demonstrates the Clinical Trial Results
of Aptivus Capsules II-78
GlaxoSmithKline Demonstrates Results for H5N1 Pandemic Flu
Vaccine Clinical Trials II-79
GlaxoSmithKline Minimizes Prices of HIV Drugs in Poor Countries II-79
Donations Rises for AIDS Orphanage in South Africa II-79
FDA to Ban the Usage of Human Antiviral Drugs for Influenza
Treatment in Poultry II-79
Third Wave Withdraws Lawsuit against Digene Relating to
Patent on HPV Drug II-80
Roche Files Suit against Ranbaxy to Restrain Launch of
Antiviral Generic Drug II-80
Dainippon Pharmaceutical to Merge with Sumitomo Pharmaceuticals II-80
Abbott and OraSure Enter into Agreement II-80
Hemispherx Biopharma Signs a Research Agreement with Defence
R&D Canada II-80
LUPIN and Cornerstone Sign Licensing Agreement to Develop
Anti-Infective Product II-81
Trimeris Inc Enters into Collaborative Agreement with
ChemBridge Research Laboratories II-81
Corixa Corporation Collaborates with Lorantis II-81
Takeda Enters into HPV Collaborative Agreement with 3M II-81
MedImmune Inks Collaborative Licensing Agreement with Biota II-82
Pharmasset Enters into License Agreement with Bukwang Pharm II-82
Chiron and Enanta Pharmaceuticals Enter into HCV PI
Development Agreement II-82
Gilead Sciences Enters into JTK-303 License Agreement with
Japan Tobacco II-82
Alnylam and Isis Enter into Licensing Deal with Stanford
University II-83
Gen-Probe and F. Hoffmann-La Roche Enter into an Agreement II-83
SciGen Limited Enters into Hepatitis B Vaccine Distribution
Agreement with Berna Biotech AG II-83
GSK Receives Supply Order for Relenza from Governments of
Three Countries II-84
Bristol-Myers to Establish Production Facility in China II-84
Koronis Initiates Phase 1b Trial for KP-1461 Antiviral II-84
Gilead Initiates Phase III Clinical Trials for Tenofovir II-84
Vaccine Research Center Initiates Phase II Trials on Adenovector II-84
Aethlon Medical Instigates Clinical Trials of HCV II-85
Hemispherx Biopharma Initiates Alferon LDO Clinical Trials II-85
Bristol-Myers and Merck Provide IPM with License to Develop
HIV Vaccines II-85
Hi-Tech's Acyclovir Oral Suspension Secures FDA Approval II-85
Bristol-Myers Squibb Gains FDA Approval for the company's
Entecavir II-85
Corixa's Fendrix Vaccine Receives European Approval II-86
Calypte Biomedical's HIV-1 Urine EIA Screening Test Receives
FDA Approval II-86
Gilead Sciences's Truvada Receives Marketing Authorization II-86
Abbott Receives FDA Approval to Formulate Kaletra in Tablet Form II-86
Boehringer Ingelheim Receives EU Approval to Market Aptivus II-86
Boehringer Ingelheim Secures FDA Approval to Market Aptivus II-87
SciClone Releases Poster Presentation of Zadaxin Triple Therapy II-87
GlaxoSmithKline Discloses Clinical Findings for Brecanavir II-87
Abbott and Celera Secure CE Mark Certification for PCR Test II-87
Gilead Sciences Cuts Prices for Truvada and Viread for
Developing Nations II-87
Gilead Sued Roche for not Properly Marketing Tamiflu and
Receives Damage Payment II-88
MGI PHARMA to Purchase Zycos II-88
Benitec Ltd Acquires Avocel Inc II-88
ID Biomedical Takes Over Vaccine Business of Shire II-88
SGX Forms Alliance with Roche to Develop New Antivirals II-89
Epimmune and Innogenetics Extend Collaboration Agreement II-89
Nucleonics and Novosom Collaborate to Develop New Antivirals II-89
Gilead Sciences and Achillion Pharmaceuticals Sign Licensing
Agreement II-89
ZymoGenetics Licenses Drug Development Rights to Novo Nordisk II-90
Cubist and XTL Sign Development Agreement II-90
Sunesis and Merck Signs Research Agreement II-90
CytoGenix Files Pre-IND Brief with the FDA II-90
ViroPharma Signs Licensing Agreement with Schering-Plough II-91
Hemispherx Inks Agreement with GMC for Development and
Commercialization of HIV Antivirals II-91
DNA-C and NYVAC Combination AIDS Vaccine To Enter Clinical
Trial Stage II-91
GlaxoSmithKline Plc Reduces Anti-AIDS Treatment Prices in
Poor Countries II-91
Gilead Acquires Triangle Pharmaceuticals II-92
Micrologix Acquires Antivirals Portfolio of Origenix II-92
Roche Acquires HPV Patent Portfolio from Pasteur Institute II-92
Johnson & Johnson Enters into an Agreement to Acquire
Tibotec-Virco NV II-92
USL Signs Licensing Agreement with Novactyl II-92
Micrologix Biotech and Hybridon Signs Collaborative Licensing
Agreement II-93
Novartis Acquires a Portfolio of Antivirals from SmithKline
Beecham II-93
Biota Inc's Bird Flu Drug Relenza Receives FDA Approval II-93
10. Focus on Select Key Players II-94
Abbott Laboratories (USA) II-94
Boehringer Ingelheim (Germany) II-94
Bristol-Myers Squibb (USA) II-94
Gilead Sciences (USA) II-95
GlaxoSmithKline Plc. (UK) II-95
Hoffmann-La Roche (Switzerland) II-96
Merck & Co. (USA) II-97
Novartis AG (Switzerland) II-97
Pfizer Inc. (USA) II-98
Schering-Plough Corp. (USA) II-98
11. Global Market Perspective II-99
Table 26: World Recent Past, Current & Future Analysis for
Antivirals by Geographic Region - US, Japan, Europe and Rest
of World (excluding Japan) Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-99
Table 27: World Recent Past, Current & Future Analysis for
Antivirals by Product Segment - HIV Antivirals (RTIs {NRTIs
and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C
Antivirals (Hepatitis C Antivirals and Hepatitis B
Antivirals), HSV Antivirals, Influenza Antivirals, RSV
Antivirals, HPV Antivirals, and Other Antivirals Independently
Analyzed by Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-100
Table 28: World 10-Year Perspective for Antivirals by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World (excluding Japan) for
Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-101
Table 29: World 10-Year Perspective for Antivirals by Product
Segment - Percentage Breakdown of Dollar Sales for HIV
Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV
Antivirals), Hepatitis B & C Antivirals (Hepatitis C
Antivirals and Hepatitis B Antivirals), HSV Antivirals,
Influenza Antivirals, RSV Antivirals, HPV Antivirals, and
Other Antivirals for Years 2000, 2006 & 2010 (includes
corresponding Graph/Chart) II-102
Table 30: World Recent Past, Current & Future Analysis for HIV
Antivirals by Geographic Region - US, Japan, Europe and Rest
of World (excluding Japan) Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-103
Table 31: World 10-Year Perspective for HIV Antivirals by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe and Rest of World (excluding Japan) Markets
for Years 2000, 2006 & 2010 (includes corresponding
Graph/Chart) II-103
Table 32: World Recent Past, Current & Future Analysis for
Hepatitis B & C Antivirals by Geographic Region - US, Japan,
Europe and Rest of World (excluding Japan) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-104
Table 33: World 10-Year Perspective for Hepatitis B & C
Antivirals by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World
(excluding Japan) Markets for Years 2000, 2006 & 2010
(includes corresponding Graph/Chart) II-104
Table 34: World Recent Past, Current & Future Analysis for
Hepatitis C Antivirals by Geographic Region - US, Japan,
Europe and Rest of World (excluding Japan) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-105
Table 35: World 10-Year Perspective for Hepatitis C
Antivirals by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World
(excluding Japan) Markets for Years 2000, 2006 & 2010
(includes corresponding Graph/Chart) II-105
Table 36: World Recent Past, Current & Future Analysis for
Hepatitis B Antivirals by Geographic Region - US, Japan,
Europe and Rest of World (excluding Japan) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-106
Table 37: World 10-Year Perspective for Hepatitis B
Antivirals by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Japan, Europe and Rest of World
(excluding Japan) Markets for Years 2000, 2006 & 2010
(includes corresponding Graph/Chart) II-106
III. MARKET
1. The United States III-1
A.Market Analysis III-1
Infectious Disease Drugs Market in the US III-1
Table 38: Infectious Disease Drugs Market by Class in the
US: 2005 Percentage Share Breakdown by Type for
Quinolones, Penicillins, Macrolides, Antifungals,
Cephalosporins, Antivirals, Tetracyclines, Erythromycins
and Other Therapies in US$ million (includes corresponding
Graph/Chart) III-1
Antivirals Market Perspective in the US III-1
HIV Antivirals Dominate the Antiviral Therapies Market in
the US, followed by the Hepatitis B & C Antivirals Class III-1
Table 39: Antivirals Market by Type in the US: 2006
Percentage Share Breakdown for HIVAntivirals, Hepatitis B &
C Antivirals, and Other Antivirals (includes corresponding
Graph/Chart) III-2
Combivir Dominates the Reverse Transcriptase Inhibitors
Market in the US III-2
Table 40: Reverse Transcriptase Inhibitors Market by Brand
Type in the US: 2005 Percentage Share Breakdown for
Combivir, Zerit, Epivir, Sustiva, Viramune, Ziagen, Videx,
Retrovir and *Others (includes corresponding Graph/Chart) III-2
Table 41: Leading Players in the HIV Reverse Transcriptase
Inhibitors (RTIs) Market in the US: 2005 Percentage Share
Breakdown for Glaxo SmithKline, Bristol-Myers Squibb and
*Others (includes corresponding Graph/Chart) III-3
Viracept Dominates the Protease Inhibitors Market in the US III-3
Table 42: Protease Inhibitors Market by Brand Type in the
US: 2005 Percentage Share Breakdown for Viracept, Crixivan,
Norvir, Fortovase, Agenerase and Invirase (includes
corresponding Graph/Chart) III-3
Table 43: Leading Players in the HIV Protease Inhibitors
(PIs) Market in the US: 2005 Percentage Share Breakdown
for Abbott Laboratories, Pfizer and *Others (includes
corresponding Graph/Chart) III-3
Hepatitis B Infection Prevalence in the US III-3
Hepsera Dominates the Oral Hepatitis B Antivirals Market III-4
Table 44: Leading Brands in the Oral Hepatitis B Antivirals
Market in the US: 2006 Percentage Share Breakdown for
Hepsera, Epivir HBV and Baraclude (includes corresponding
Graph/Chart) III-4
New Emerging Therapies for HBV Infection in the US III-4
Emerging Hepatitis B Infection Antivirals in Phase II
Clinical Trials in the US III-5
Emerging Hepatitis B Infection Antivirals in Phase I
Clinical Trials in the US III-5
Hepatitis C Antivirals Market in the US III-5
Table 45: Leading Players in the Hepatitis C Antivirals
Market in the US: 2005 Percentage Share Breakdown for
Schering Plough and *Others III-6
Table 46: Leading Brands in the Interferon Hepatitis C
Antivirals Market in the US: 2006 Percentage Share
Breakdown for Pegasys, PEG Intron, Copegus and Rebetol
(includes corresponding Graph/Chart) III-6
HSV Antivirals in the US III-6
Table 47: Leading Players in the HSV Antivirals Market in
the US: 2005 Percentage Share Breakdown for Glaxo
SmithKline, Generics and *Others (includes corresponding
Graph/Chart) III-6
Influenza Antivirals Market in the US III-7
Emerging Influenza Antivirals in the Clinical Development
Stage in the US III-7
TIV Dominates the US Influenza Vaccines Market III-7
Table 48: Influenza Vaccines Market in the US: 2006
Percentage Share Breakdown by Vaccine Type for Treated
(Killed) Influenza Vaccine (TIV) and Live Attenuated
Influenza Vaccine (LAIV) III-7
Fluzone Rules the Roost in the Influenza Vaccines Market III-7
Table 49: Influenza Vaccines Market in the US: 2006
Percentage Share Breakdown by Vaccine Brand for Fluzone,
Fluvirin, Fluarix and FluMist (includes corresponding
Graph/Chart) III-8
Table 50: Leading Players in the Influenza Antivirals
Market in the US: 2005 Percentage Share Breakdown for Roche
and *Others III-8
HIV/AIDS Prevalence in the US III-8
Homosexual Males Emerges as a Significant Risk Group for
HIV Infections in the US III-9
Table 51: Diagnosis of HIV/AIDS among Adult and Adolescent
Males in the US: 2005 Percentage Share Breakdown by
Transmission Category for Homosexual Contact, Heterosexual
Contact, Injecting Drug User (IDU), Homosexual Contact &
IDU and Others (includes corresponding Graph/Chart) III-9
Table 52: Ethnic Group Distribution of HIV/AIDS Cases Among
Men with Homosexual Contacts in the US: 2005 Percentage
Share Breakdown for Whites, African Americans, Latin
Americans, Asian/Pacific Islander and American
Indian/Alaska Native (includes corresponding Graph/Chart) III-10
Women, a High Risk Group for HIV/AIDS in the US III-10
Table 53: AIDS Cases Reported in the US Among Females 13
and Older: 2005 Percentage Share Breakdown by Ethnic
Community for African American Women, Latin American
Women, White Women and Others (includes corresponding
Graph/Chart) III-10
Table 54: Diagnosis of HIV/AIDS among Adult and Adolescent
Females in the US: 2005 Percentage Share Breakdown by
Transmission Category for Heterosexual Contact, Injecting
Drug User (IDU) and Others (includes corresponding
Graph/Chart) III-10
African Americans, the Leading High Risk Ethnic Group for
HIV Infection in the US III-11
Table 55: Individuals Living with AIDS in the US: 2005
Percentage Share Breakdown by Ethnic Community for African
Americans, Whites, Latin Americans and Others (includes
corresponding Graph/Chart) III-11
Latinos, the Second Major Ethnic Risk Group for HIV
Infection in the US III-11
Zidovudine (ZDV) Emerges as a Major Drug to Prevent
Mother-to-Child Transmission of HIV Infection III-11
An Overview of Sexually Transmitted Diseases (STDs) in the US III-11
Regulatory Environment for HIV/AIDS in the US III-12
Product Launches III-12
Strategic Corporate Developments III-14
Focus on Key Players III-27
3M III-27
Abbott Laboratories III-27
Amazon Biotech III-28
Bristol-Myers Squibb III-28
FermaVir Pharmaceuticals III-29
Gilead Sciences III-29
Hemispherx Biopharma III-29
MedImmune Inc. III-30
Merck & Co. III-30
Novartis Pharmaceuticals III-30
Novelos Therapeutics III-31
Panacos Pharmaceuticals III-31
Pfizer Inc. III-31
Pharmasset III-31
Schering-Plough Corporation III-32
B.Market Analytics III-32
Table 56: US Recent Past, Current & Future Analysis for
Antivirals Market Independently Analyzed by Annual Sales for
the Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-32
Table 57: US Recent Past, Current & Future Analysis for HIV
Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs
and Other HIV Antivirals Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-33
Table 58: US 10-Year Perspective for HIV Antivirals by
Product Segment - Percentage Breakdown of Value Sales for
RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for
the Years 2000, 2006 & 2010 (includes corresponding
Graph/Chart) III-33
Table 59: US Recent Past, Current & Future Analysis for
Hepatitis B & C Antivirals by Product Segment - Hepatitis C
Antivirals and Hepatitis B Antivirals Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$
Million (includes corresponding Graph/Chart) III-34
Table 60: US 10-Year Perspective for Hepatitis B & C
Antivirals by Product Segment - Percentage Breakdown of
Value Sales for Hepatitis C Antivirals and Hepatitis
BAntivirals for the Years 2000, 2006 & 2010 III-34
2. Japan III-35
A.Market Analysis III-35
Japanese Antivirals Market Perspective III-35
HIV Infection Prevalence in Japan III-35
Hepatitis B & C Antivirals Dominate the Japanese Antivirals
Market III-35
Japan, the Second Largest Market for Hepatitis C Infection
in the World III-35
Table 61: Leading Drug Brands for Hepatitis C Antivirals in
Japan: 2005, 2006 and 2008E Percentage Share Breakdown for
PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon,
Feron and Others (includes corresponding Graph/Chart) III-36
Product Launch III-36
Strategic Corporate Developments III-36
Focus on Key Players III-37
Daiichi Pharmaceutical Co. III-37
Japan Tobacco III-38
B.Market Analytics III-38
Table 62: Japanese Recent Past, Current & Future Analysis
for Antivirals Market Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-38
Table 63: Japanese Recent Past, Current & Future Analysis
for HIV Antivirals Market Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-39
Table 64: Japanese Recent Past, Current & Future Analysis
for Hepatitis B & C Antivirals by Product Segment -
Hepatitis C Antivirals and Hepatitis B Antivirals
Independently Analyzed by Annual Sales for the Years 2000
through 2010 in US$ Million (includes corresponding
Graph/Chart) III-39
Table 65: Japanese 10-Year Perspective for Hepatitis B & C
Antivirals by Product Segment - Percentage Breakdown of
Value Sales for Hepatitis C Antivirals and Hepatitis B
Antivirals for the Years 2000, 2006 & 2010 III-39
3. Europe III-40
A.Market Analysis III-40
France - The Largest and the Fastest Growing Market for
Antivirals III-40
HIV Therapy Dominates the Antivirals Market III-40
Table 66: Antivirals Market by Type in Europe: 2006
Percentage Share Breakdown for HIV Antivirals, Hepatitis B
& C Antivirals, and Other Antivirals (includes
corresponding Graph/Chart) III-40
HIV/AIDS Prevalence in Europe III-41
HIV/AIDS Statistics in Western Europe III-41
UK Dominates the Market for Western Europe for HIV Infection III-41
Table 67: Diagnosis of HIV Infection among Adults in
Western Europe: 2005 Percentage Share Breakdown by Region
for UK, Portugal, **France, Germany, The Netherlands,
*Italy, Belgium, Switzerland and Others (includes
corresponding Graph/Chart) III-41
HIV/AIDS Statistics in Central Europe III-42
Poland Dominates the Market for Central Europe for HIV
Infection III-42
Table 68: Diagnosis of HIV Infection among Adults in
Central Europe: 2005 Percentage Share Breakdown by Region
for Poland, Romania, Turkey, Serbia & Montenegro, Czech
Republic, Hungary, Bulgaria and Others (includes
corresponding Graph/Chart) III-42
HIV/AIDS Statistics in Eastern Europe III-42
Russia Dominates the Market for Eastern Europe for HIV
Infection III-42
Table 69: Diagnosis of HIV Infection among Adults in
Eastern Europe: 2005 Percentage Share Breakdown by Region
for Russia, *Ukraine, Uzbekistan, Belarus, Estonia,
Kazakhstan, Republic of Moldova, Latvia and Others
(includes corresponding Graph/Chart) III-43
Herpes Antivirals III-43
Strategic Corporate Developments III-43
B.Market Analytics III-46
Table 70: European Recent Past, Current & Future Analysis
for Antivirals by Geographic Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed by Annual Sales for the Years 2000 through 2010 in
US$ Million (includes corresponding Graph/Chart) III-46
Table 71: European 10-Year Perspective for Antivirals by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain and Rest of Europe for
Years 2000, 2006 & 2010 (includes corresponding
Graph/Chart) III-46
Table 72: European Recent Past, Current & Future Analysis
for HIV Antivirals by Product Segment - RTIs (NRTIs and
NNTRIs), PIs and Other HIV Antivirals Independently Analyzed
by Annual Sales for the Years 2000 through 2010 in US$
Million (includes corresponding Graph/Chart) III-47
Table 73: European 10-Year Perspective for HIV Antivirals
by Product Segment -Percentage Breakdown of Value Sales for
RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for
Years 2000, 2006 & 2010 (includes corresponding
Graph/Chart) III-47
Table 74: European Recent Past, Current & Future Analysis
for Hepatitis B & C Antivirals by Product Segment -
Hepatitis C Antivirals and Hepatitis B Antivirals
Independently Analyzed by Annual Sales for the Years 2000
through 2010 in US$ Million (includes corresponding
Graph/Chart) III-48
Table 75: European 10-Year Perspective for Hepatitis B & C
Antivirals by Product Segment- Percentage Breakdown of
Value Sales for Hepatitic C Antivirals and Hepatitis B
Antivirals for Years 2000, 2006 & 2010 III-48
3a. France III-49
A.Market Analysis III-49
France the Largest and Fastest Growing Antivirals Market in
Europe III-49
Strategic Corporate Developments III-49
B.Market Analytics III-49
Table 76: French Recent Past, Current & Future Analysis for
Antivirals Independently Analyzed by Annual Sales for the
Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-49
3b. Germany III-50
A.Market Analysis III-50
Germany the Second Largest and Fastest Growing Antivirals
Market in Europe III-50
Strategic Corporate Developments III-50
Focus on Key Player III-51
Boehringer Ingelheim III-51
B.Market Analytics III-51
Table 77: German Recent Past, Current & Future Analysis for
Antivirals Independently Analyzed by Annual Sales for the
Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-51
3c. Italy III-52
A.Market Analysis III-52
Strategic Corporate Developments III-52
B.Market Analytics III-52
Table 78: Italian Recent Past, Current & Future Analysis
for Antivirals Independently Analyzed by Annual Sales for
the Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-52
3d. The United Kingdom III-53
Market Analysis III-53
UK the Third Largest Market for Antivirals in Europe III-53
HIV/AIDS Prevalence in the UK III-53
Table 79: Diagnosis of HIV Infection among Individuals in
the UK: 2005 Percentage Share Breakdown by Ethnic Community
for Whites, Black- Africans, Black-Caribbeans and Others
(includes corresponding Graph/Chart) III-53
Table 80: Diagnosis of AIDS among Adult Males in the UK:
2005 Percentage Share Breakdown by Transmission Category
for Homosexual Contact, Heterosexual Contact, Injecting
Drug Use (IDU), Blood/Tissue Transfer or Blood Factor and
Others (includes corresponding Graph/Chart) III-54
Table 81: Diagnosis of AIDS among Adult Females in the UK:
2005 Percentage Share Breakdown by Transmission Category
for Heterosexual Contact, Injecting Drug Use (IDU),
Mother-to-Child Transfer, Blood/Tissue Transfer or Blood
Factor and Others (includes corresponding Graph/Chart) III-54
Table 82: Diagnosis of HIV Infection in People in the UK:
2005 Percentage Share Breakdown by Region for England,
Scotland, Wales and North Ireland (includes corresponding
Graph/Chart) III-54
Drug Resistant HIV Strains Rising in the UK III-54
Rise in Sexually Transmitted Diseases Pose Health Risks III-54
Strategic Corporate Developments III-55
Focus on Key Player III-55
GlaxoSmithKline PLC III-55
B.Market Analytics III-56
Table 83: UK Recent Past, Current & Future Analysis for
Antivirals Independently Analyzed by Annual Sales for the
Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-56
3e. Spain III-57
A.Market Analysis III-57
B.Market Analytics III-57
Table 84: Spanish Recent Past, Current & Future Analysis
for Antivirals Independently Analyzed by Annual Sales for
the Years 2000 through 2010 in US$ Million (includes
corresponding Graph/Chart) III-57
3f. Rest of Europe III-58
A.Market Analysis III-58
Russia III-58
Acute Supply Shortage of AIDS drugs Risks the Life of Many
People in Russia III-58
Strategic Corporate Developments III-58
Focus on Key Players III-60
Hoffmann-La Roche (Switzerland) III-60
Novartis AG (Switzerland) III-61
B.Market Analytics III-61
Table 85: Rest of Europe Recent Past, Current & Future
Analysis for Antivirals Independently Analyzed by Annual
Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-61
4. Rest of World III-62
A.Market Analysis III-62
Canada III-62
HIV/AIDS Prevalence in Canada III-62
Table 86: Diagnosis of HIV Infection among Adult Males in
Canada: 2005 Percentage Share Breakdown by Transmission
Category for Homosexual Contact, Heterosexual Contact,
Injecting Drug Use (IDU), Homosexual Contact & IDU,
Infection through Blood/Blood Products and Others (includes
corresponding Graph/Chart) III-62
Table 87: Diagnosis of HIV Infection among Adult Females in
Canada: 2005 Percentage Share Breakdown by Transmission
Category for Heterosexual Contact, Injecting Drug Use
(IDU), Infection through Blood/Blood Products and Others
(includes corresponding Graph/Chart) III-63
Table 88: Diagnosis of AIDS among Adult Males in Canada:
2005 Percentage Share Breakdown by Transmission Category
for Homosexual Contact, Heterosexual Contact, Injecting
Drug Use (IDU), Homosexual Contact & IDU and Others
(includes corresponding Graph/Chart) III-63
Table 89: Diagnosis of AIDS among Adult Females in Canada:
2005 Percentage Share Breakdown by Transmission Category
for Heterosexual Contact, Injecting Drug Use (IDU) and
Others (includes corresponding Graph/Chart) III-63
Table 90: Individuals Living with AIDS in Canada: 2005
Percentage Share Breakdown by Ethnic Community for Whites,
Aboriginals, Blacks, South Asian/West Asian/Arab, Asians
and Others (includes corresponding Graph/Chart) III-64
Hepatitis C Infection Prevalence in Canada III-64
Asia-Pacific III-64
HIV/AIDS Prevalence in Asia III-64
HIV Infection Among Males Rising III-64
Australia III-65
HIV/AIDS Prevalence in Australia III-65
Table 91: Diagnosis of HIV Infections in Australia: 2005
Percentage Share Breakdown by Region for New South Wales,
Victoria, Queensland, Western Australia, South Australia,
Australian Capital Territory and Others (includes
corresponding Graph/Chart) III-65
Hepatitis C Infection Prevalence in Australia III-65
Table 92: Sources of Hepatitis C Infection Transmission in
Australia: 2005 Percentage Share Breakdown by Transmission
Category for Injecting Drug Use (IDU), Blood
Transfusion/Medical, Tattoos/Piercing, Sexual Contact and
Others (includes corresponding Graph/Chart) III-66
Bangladesh III-66
HIV/AIDS Prevalence in Bangladesh III-66
Cambodia III-66
HIV/AIDS Prevalence in Cambodia III-66
China III-66
Antivirals Market in China III-66
China Presents a Major Market for Hepatitis B Therapies III-67
HIV/AIDS Prevalence in China III-67
Hong Kong III-67
HIV/AIDS Prevalence in Hong Kong III-67
India III-68
Hepatitis B Vaccines Market in India III-68
Table 93: Hepatitis B Vaccine Market in India: 2005
Percentage Share Breakdown by Player for Shantha Biotech,
Glaxo SmithKline and Others (includes corresponding
Graph/Chart) III-68
HIV/AIDS Prevalence in India III-68
Table 94: AIDS Cases Diagnosed in India: 2005 Percentage
Share Breakdown by Gender for Males and Females III-69
Table 95: Diagnosis of HIV/AIDS Cases in India: 2005
Percentage Share Breakdown by Transmission Category for
Sexual Contact, Mother-to-Child Transfer, Injecting Drug
Use (IDU), Blood and Blood Products, and Others (includes
corresponding Graph/Chart) III-69
Table 96: Diagnosis of AIDS Cases in India: 2005
Percentage Share Breakdown by Geographic Region for Tamil
Nadu, Maharashtra, Andhra Pradesh, Karnataka, Manipur, West
Bengal, Kerala, Madhya Pradesh, Uttar Pradesh, Rajasthan
and Others (includes corresponding Graph/Chart) III-69
India Emerging as a Major Market for HIV-Infected People
in the World III-70
Table 97: Diagnosis of HIV Infection in India: 2005
Percentage Share Breakdown by Sub-Population for General
Population, STD Patients, Injecting Drug Users (IDUs),
Children and Female Sex Workers (FSWs) (includes
corresponding Graph/Chart) III-70
Organizations Active in Executing HIV/AIDS Control and
Prevention Programs III-70
Table 98: Institutional Funding for HIV/AIDS Control
Programs in India: 2005 Percentage Share Breakdown by
Funding Organization for Public Bodies, Bilateral
Organizations, World Bank, Multilateral Organizations and
Global Funds (includes corresponding Graph/Chart) III-71
India Steps Up Infrastructure Development to Control and
Prevent the Spread of Viral Infections III-71
New Treatment Options to Fight Against HIV Infection III-71
AIDS Control Programs for Rural Youths in India III-72
Indonesia III-72
HIV/AIDS Prevalence in Indonesia III-72
Myanmar (Burma) III-72
HIV/AIDS Prevalence in Myanmar III-72
Nepal III-72
HIV/AIDS Prevalence in Nepal III-72
New Zealand III-73
HIV/AIDS Prevalence in New Zealand III-73
Pakistan III-73
HIV/AIDS Prevalence in Pakistan III-73
Singapore III-73
HIV/AIDS Prevalence in Singapore III-73
South Korea III-73
HIV/AIDS Prevalence in South Korea III-73
Thailand III-73
HIV/AIDS Prevalence in Thailand III-73
Viet Nam III-74
HIV/AIDS Prevalence in Viet Nam III-74
Hepatitis B Infection Prevalence in Viet Nam III-74
Latin America III-74
HIV/AIDS Prevalence in Latin America III-74
Table 99: Diagnosis of People Living with HIV/AIDS in
Latin America: 2005 Percentage Share Breakdown by
Geographic Region for Brazil, Mexico, Colombia, Argentina,
Venezuela, Peru, Honduras, Guatemala, El Salvador,
Ecuador, Panama, Paraguay and Others (includes
corresponding Graph/Chart) III-75
Table 100: Diagnosis of AIDS Related Deaths in Latin
America: 2005 Percentage Share Breakdown by Geographic
Region for Brazil, Colombia, Mexico, Venezuela, Peru,
Argentina, Honduras, Guatemala, El Salvador, Ecuador,
Panama and Others (includes corresponding Graph/Chart) III-75
HIV/AIDS Prevalence in the Caribbean Region III-76
Table 101: Diagnosis of People Living with HIV/AIDS in
Caribbean: 2005 Percentage Share Breakdown by Geographic
Region for Haiti, Dominican Republic, Trinidad and Tobago,
Jamaica, Bahamas, Cuba and Barbados (includes corresponding
Graph/Chart) III-76
Table 102: Diagnosis of AIDS Related Deaths in Caribbean:
2005 Percentage Share Breakdown by Geographic Region for
Haiti, Dominican Republic, Trinidad and Tobago, Jamaica and
Others (includes corresponding Graph/Chart) III-77
Africa III-77
HIV/AIDS Prevalence in Sub-Saharan Africa III-77
Table 103: Diagnosis of People Living with HIV/AIDS in
Sub-Saharan Africa: 2005 Percentage Share Breakdown by
Geographic Region for South Africa, Nigeria, Mozambique,
Zimbabwe, United Republic of Tanzania, Kenya, Ethiopia,
Zambia, Democratic Republic of Congo, Uganda and Others
(includes corresponding Graph/Chart) III-77
Table 104: Diagnosis of AIDS Related Deaths in Sub-Saharan
Africa: 2005 Percentage Share Breakdown by Geographic
Region for South Africa, Nigeria, Zimbabwe, Mozambique,
United Republic Of Tanzania, Kenya, Ethiopia, Zambia,
Uganda, Malawi and Others (includes corresponding
Graph/Chart) III-78
Table 105: Diagnosis of AIDS Related Orphans in
Sub-Saharan Africa: 2005 Percentage Share Breakdown by
Geographic Region for South Africa, Kenya, United Republic
Of Tanzania, Zimbabwe, Uganda, Nigeria, Ethiopia, Zambia,
Democratic Republic of Congo, Malawi and Others (includes
corresponding Graph/Chart) III-78
South Africa III-79
Television Exposures Induces Healthy Lifestyle Changes
Among People to Combat HIV/AIDS Epidemic III-79
HIV/AIDS Prevalence in South Africa III-79
Middle East III-79
HIV/AIDS Prevalence in Middle East III-79
Product Launches III-80
Strategic Corporate Developments III-81
Focus on Select Players III-85
Bukwang Pharm (South Korea) III-85
Benitec Limited (Australia) III-85
B.Market Analytics III-85
Table 106: Rest of World Recent Past, Current & Future
Analysis for Antivirals Market Independently Analyzed by
Annual Sales for the Years 2000 through 2010 in US$ Million
(includes corresponding Graph/Chart) III-85
Table 107: Rest of World Recent Past, Current & Future
Analysis for Hepatitis B & C Antivirals by Product Segment -
Hepatitis C Antivirals and Hepatitis B Antivirals
Independently Analyzed by Annual Sales for the Years 2000
through 2010 in US$ Million (includes corresponding
Graph/Chart) III-86
Table 108: Rest of World 10-Year Perspective for Hepatitis
B & C Antivirals by Product Segment - Percentage Breakdown
of Value Sales for Hepatitis C Antivirals and
Hepatitis B Antivirals for the Years 2000, 2006 & 2010
(includes corresponding Graph/Chart) III-86
Table 109: Rest of World 10-Year Perspective for Hepatitis
B & C Antivirals by Product Segment - Percentage Breakdown
of Value Sales for Hepatitis C Antivirals and Hepatitis B
Antivirals for the Years 2000, 2006 & 2010 III-86
IV. COMPETITIVE LANDSCAPE
Warranty Information
This report is offered in PDF format via e-mail. Once downloaded, the PDF can’t be copied to another computer. The user is permitted to print one full copy of the report. Extra copies or licenses may be purchased at 10% of the list price.
Find Similar Products by Category
Currency Converter
Choose a currency below to display product prices in the selected currency.
Add to Wish List
You Recently Viewed...
All prices are in USD. Copyright 2010 Electronics.ca Publications.
|
| About Us | Contact us | Ordering Information | RSS | Terms and Conditions | Privacy policy |
Electronics.ca™ is a global research network serving the industry, corporations and investment banks. |
